Navigation Links
Stereotaxis Annouces First CTO Crossing Procedure With RF PowerAssert(TM) Magnetic Guidewire
Date:1/12/2009

ST. LOUIS, Jan. 12 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq: STXS) today announced the first crossing of a chronic total occlusion using the RF PowerAssert(TM) Magnetic Guidewire. Cleared by the U.S. Food and Drug Administration in 2008, the RF PowerAssert guidewire is the only magnetically enabled device available for crossing peripheral occlusions, including CTOs. Used with the Niobe Magnetic Navigation System, it is an innovative solution that enables precise intra-lesion control of its distal tip.

Austin Heart interventional cardiologist Frank Zidar, M.D. used the new device on January 7th, on a patient with severe peripheral artery disease (PAD). The patient had 100% blockage in a main artery in his leg that caused chronic, severe pain due to poor circulation.

"This new magnetic guidewire technology provided great control and improved accuracy over traditional, manual guidewires," said Dr. Zidar. "Once we reached the blockage, the tip of the guidewire burned a tiny passage through the blockage, allowing us then to use existing techniques to open up the blockage further and restore healthy blood flow to the patient's leg. This revolutionary technology will likely reduce procedures times, and therefore reduce the amount of contrast dye and imaging radiation to the patient."

Dr. Zidar performed this procedure at Heart Hospital of Austin.

"This is a promising beginning for our RF PowerAssert guidewire," said Michael P. Kaminski, Stereotaxis President and CEO. "We are delighted that Dr. Zidar was able to provide this patient with a positive outcome, and are very excited to work with other clinicians across the country as they adopt our magnetically-enabled technologies in their vascular labs."

For more information about Stereotaxis or its magnetic vascular lab technologies, visit http://www.stereotaxis.com.

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe and Canada.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company's products in the marketplace, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.


'/>"/>
SOURCE Stereotaxis, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Stereotaxis to Raise $20 Million in Registered Direct Offering of Common Stock and Warrants
2. Stereotaxis Reports Third Quarter 2008 Financial Results
3. Stereotaxis Announces New Management Appointment
4. Stereotaxis Reports Record Second Quarter Revenue
5. Stereotaxis Announces Second Quarter 2008 Earnings Release Date and Conference Call
6. Stereotaxis Magnetic Navigation System Used to Successfully Treat an Inoperable Congenital Heart Defect in a 10-Year Old Patient
7. Stereotaxis Reports Record First Quarter Orders
8. Stereotaxis to Present at the Deutsche Bank 33rd Annual Health Care Conference
9. Stereotaxis Niobe Magnetic Navigation Systems Perform Approximately 15,000 Cases
10. Stereotaxis Appoints Senior Vice President of Global Marketing and General Manager for Europe
11. Stereotaxis Announces Fourth Quarter and Full Year 2007 Earnings Release Date and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
(Date:6/24/2016)... ... ... of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum Wage’ ... 2020 and then adjusting it yearly to increase at the same rate as the median ... floor does not erode again, and make future increases more predictable. , The company is ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Grove Investment Group (TGIG), has initiated cultivation and processing operations at its production ... and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Research and Markets has announced the ... (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, ... Global Forecast to 2021" report to their offering. ... pharmaceutical excipients market is projected to reach USD 8.1 ... the forecast period 2016 to 2021. ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
(Date:6/23/2016)... and INDIANAPOLIS , June 23, ... a Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, ... winners, announced today online at www.diabetesscholars.org by ... 1 diabetes stand in the way of academic and ... the Foundation,s scholarship program since 2012, and continues to ...
Breaking Medicine Technology: